photo of

Details

Role Team Leader / Senior Research Officer
Research area Stem Cell Medicine

Contact

Available for student supervision
Dr. James McNamara is a researcher in the Heart Disease and Regeneration Group at The Murdoch Children’s Research Institute. His research has focused on molecular mechanisms of hypertrophic cardiomyopathy, a common form of genetic heart disease. This research led to the discovery that mutations linked to hypertrophic cardiomyopathy increased the number of active myosin motors in mouse and human hearts, providing a mechanism for how these mutations impair contraction, relaxation, and energy utilisation. He received his PhD in Medicine from the University of Sydney in 2017. He then undertook undertake postdoctoral training at the University of Cincinnati, supported by an American Heart Association Postdoctoral Fellowship for this period and continued to focus on the function of MYBPC3, establishing a mechanism for its role in adrenergic signaling in the heart. In 2020 he joined Prof. Enzo Porrello and A/Prof David Elliott’s groups at MCRI. Here, he continues to study molecular mechanisms of genetic heart diseases, now utilising human pluripotent stem cells as a human model of disease. James’ research is currently supported by multiple early career fellowships.
Dr. James McNamara is a researcher in the Heart Disease and Regeneration Group at The Murdoch Children’s Research Institute. His research has focused on molecular mechanisms of hypertrophic cardiomyopathy, a common form of genetic heart disease. ...
Dr. James McNamara is a researcher in the Heart Disease and Regeneration Group at The Murdoch Children’s Research Institute. His research has focused on molecular mechanisms of hypertrophic cardiomyopathy, a common form of genetic heart disease. This research led to the discovery that mutations linked to hypertrophic cardiomyopathy increased the number of active myosin motors in mouse and human hearts, providing a mechanism for how these mutations impair contraction, relaxation, and energy utilisation. He received his PhD in Medicine from the University of Sydney in 2017. He then undertook undertake postdoctoral training at the University of Cincinnati, supported by an American Heart Association Postdoctoral Fellowship for this period and continued to focus on the function of MYBPC3, establishing a mechanism for its role in adrenergic signaling in the heart. In 2020 he joined Prof. Enzo Porrello and A/Prof David Elliott’s groups at MCRI. Here, he continues to study molecular mechanisms of genetic heart diseases, now utilising human pluripotent stem cells as a human model of disease. James’ research is currently supported by multiple early career fellowships.

Top Publications

  • Robbins, N, Gilbert, M, Kumar, M, McNamara, JW, Daly, P, Koch, SE, Conway, G, Effat, M, Woo, JG, Sadayappan, S, et al. Probenecid Improves Cardiac Function in Patients With Heart Failure With Reduced Ejection Fraction In Vivo and Cardiomyocyte Calcium Sensitivity In Vitro.. J Am Heart Assoc 7(2) : 2018
    view publication
  • Grimes, KM, Barefield, DY, Kumar, M, McNamara, JW, Weintraub, ST, de Tombe, PP, Sadayappan, S, Buffenstein, R. The naked mole-rat exhibits an unusual cardiac myofilament protein profile providing new insights into heart function of this naturally subterranean rodent.. Pflugers Arch 469(12) : 1603 -1613 2017
    view publication
  • Dos Remedios, CG, Lal, SP, Li, A, McNamara, J, Keogh, A, Macdonald, PS, Cooke, R, Ehler, E, Knöll, R, Marston, SB, et al. The Sydney Heart Bank: improving translational research while eliminating or reducing the use of animal models of human heart disease.. Biophys Rev 9(4) : 431 -441 2017
    view publication
  • Nguyen, L, McNamara, J, Dos Remedios, C, Li, A, Lal, S. Increased Phosphorylation of Cardiac Myosin Binding Protein C and Increased Expression of Troponin I in Normal Human Ageing. Biophysical Journal 112(3) : 557a 2017
    view publication
  • Viswanathan, SK, Sanders, HK, McNamara, JW, Jagadeesan, A, Jahangir, A, Tajik, AJ, Sadayappan, S. Hypertrophic cardiomyopathy clinical phenotype is independent of gene mutation and mutation dosage.. PLoS One 12(11) : e0187948 2017
    view publication

Page 8 of 9